Session Information

Invited Symposium

[IS-TH-62] AOI Session: Stem Cell and Gene Therapy
Go back
print
Day
Apr 03 (Thu)
Time
13:30 - 15:00
Room
Room 19 - Imperial Hotel 2F Botan
Topic
Retina - Medical
Chair/Coordinator
Chair)Jose Sahel、Chair)Paul Sieving
Description
Lead clinicians-researchers will discuss the current status and critical steps towards developing innovative stem cell and gene therapy approaches to restore vision in currently untreatable eye diseases. The discussions will focus on a range of stem-cell and gene-therapy techniques, exploring ways to improve gene delivery to the target cells and safely reprogram cells, developing models to evaluate and overcome the challenges to successfully translate these technologies to the clinic.

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-1 / 

Retina - Medical

Needs and Opportunities for Cell and Gene Therapy

Paul Sieving

Needs and Opportunities for Cell and Gene Therapy

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-2 / 

Retina - Medical

Transplantation of Retinal Pigment Epithelial Cells Derived from iPS Cells

Masayo Takahashi

Transplantation of Retinal Pigment Epithelial Cells Derived from iPS Cells

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-3 / 

Retina - Medical

Gene Therapy in Retinal Dystrophies

Jean-Jacques De Laey

Gene Therapy in Retinal Dystrophies

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-4 / 

Retina - Medical

Gene Therapy in Retinal Dystrophies: Achievements, Actual Studies, and New Challenges

Birgit Lorenz

Gene Therapy in Retinal Dystrophies: Achievements, Actual Studies, and New Challenges

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-5 / 

Retina - Medical

Extending Cone Photoreceptors Life and Function

Jose Sahel

Extending Cone Photoreceptors Life and Function

Duration 15min (including Q&A), Panel Discussion = 0min

IS-TH-62-6 / 

Retina - Medical

Clinical Outcomes in Trials of New Treatments for Retinal Dystrophies in Man

Anthony Moore

Clinical Outcomes in Trials of New Treatments for Retinal Dystrophies in Man

Go back